Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Buyout numbers

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 23, 2023 7:03pm

170 Views

Post# 35697314

RE:RE:RE:RE:Buyout numbers

With Roche's US$ 7.1 Billion acquisition price for an experimental drug in ulcerative colitis, ONCY's buy out potential is certainly north of there, for reasons already provided including Big Pharma's looming patent cliff and Roche's strategy around Tecentriq.

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?